A randomized controlled trial of dehydroepiandrosterone in postmenopausal women with fibromyalgia

Détails

ID Serval
serval:BIB_80AB1DAE653F
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
A randomized controlled trial of dehydroepiandrosterone in postmenopausal women with fibromyalgia
Périodique
Journal of Rheumatology
Auteur⸱e⸱s
Finckh  A., Berner  I. C., Aubry-Rozier  B., So  A. K.
ISSN
0315-162X (Print)
Statut éditorial
Publié
Date de publication
07/2005
Volume
32
Numéro
7
Pages
1336-40
Notes
Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S. --- Old month value: Jul
Résumé
OBJECTIVE: Patients with fibromyalgia (FM) consistently have adrenal hyporesponsiveness and low dehydroepiandrosterone (DHEA) levels. DHEA is promoted for and used by patients with FM. We tested the efficacy and safety of DHEA supplementation in ameliorating the symptoms of FM. METHODS: In a double-blind crossover study, postmenopausal women with FM were randomized to DHEA supplementation (50 mg/day) or placebo for 3 months, with a one-month washout period in between. Patients were assessed monthly for well-being and pain and by medical evaluations at the beginning and the end of each treatment period. The primary outcome was well being; secondary outcomes were pain, fatigue, cognition, sexuality, functional impairment, depression, and anxiety. RESULTS: A total of 52 patients were randomized, 47 patients completed the DHEA treatment period, and 45 the placebo treatment period. After 3 months of treatment with 50 mg of DHEA, median DHEA sulfate blood levels had tripled, but there was no improvement in well-being, pain, fatigue, cognitive dysfunction, functional impairment, depression, or anxiety, nor in objective measurements made by physicians. Androgenic side effects (greasy skin, acne, and increased growth of body hair) were more common during the DHEA treatment period (p = 0.02). CONCLUSION: DHEA does not improve quality of life, pain, fatigue, cognitive function, mood, or functional impairment in FM.
Mots-clé
Aged Cognition/drug effects Complementary Therapies Cross-Over Studies Dehydroepiandrosterone/*administration & dosage *Dietary Supplements Double-Blind Method Female Fibromyalgia/*drug therapy Humans Middle Aged Pain/drug therapy Postmenopause Quality of Life Treatment Failure
Pubmed
Web of science
Création de la notice
25/01/2008 8:39
Dernière modification de la notice
20/08/2019 14:41
Données d'usage